Pfizer Inc. $PFE Stock: D.A. Davidson & CO. Grows Holdings

Key Points

• D.A. Davidson increased its Pfizer holdings by 6.4% in the third quarter, bringing its position to 3.30 million shares worth approximately $94 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported positive pipeline developments, including a Phase 3 success for ELREXFIO and expanded FDA approval for TALZENNA plus XTANDI, though ELREXFIO faces infection-related safety concerns and Pfizer still contends with declining COVID-product revenue and future patent expirations.
• Pfizer’s shares offered a 5.8% dividend yield based on a quarterly payout of $0.43, while analysts maintained a consensus “Hold” rating with a $28.72 price target. The company’s latest quarterly results exceeded revenue and earnings expectations.

D.A. Davidson & CO. increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,296,392 shares of the biopharmaceutical company's stock after acquiring an additional 196,916 shares during the quarter. D.A. Davidson & CO. owned about 0.06% of Pfizer worth $94,013,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Retirement Wealth Solutions LLC increased its holdings in shares of Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 509 shares during the period. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 566 shares in the last quarter. Keb Asset Management LLC bought a new stake in shares of Pfizer in the second quarter valued at approximately $26,000. Field & Main Bank bought a new stake in shares of Pfizer in the second quarter valued at approximately $27,000. Finally, Global Trust Asset Management LLC grew its position in Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 650 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: ELREXFIO delivered a Phase 3 win. Pfizer said the MagnetisMM-32 trial met its primary endpoint, showing a statistically significant and clinically meaningful progression-free-survival benefit in relapsed or refractory multiple myeloma. The result could support broader use of the drug and strengthen Pfizer’s oncology pipeline. Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint
• Positive Sentiment: The FDA expanded the approval of TALZENNA plus XTANDI for earlier-line treatment of metastatic prostate cancer in patients with HRR gene mutations. The broader indication may increase the products’ commercial opportunity and diversify revenue beyond COVID products. FDA expands Pfizer’s Talzenna plus Xtandi approval
• Positive Sentiment: Analyst sentiment remained supportive. Scotiabank and Jefferies issued Buy ratings, while previews suggested Pfizer could beat upcoming earnings expectations. Pfizer’s recent results also exceeded consensus estimates for both revenue and adjusted earnings. Pfizer gets a Buy from Scotiabank
• Neutral Sentiment: Investors are focused on the upcoming Q3 report. Strong sales from newer medicines and a relatively attractive valuation could help, but the earnings release will need to demonstrate that Pfizer can offset ongoing COVID-product declines and longer-term patent risks. Pfizer Stock Ahead of Q3 Earnings
• Negative Sentiment: ELREXFIO’s benefit came with safety concerns. Reports highlighted higher infection rates, while median progression-free survival had not yet been reached. These details may temper the market’s reaction to the otherwise positive trial results. Pfizer’s ELREXFIO meets Phase 3 endpoint
• Negative Sentiment: Valuation and business-transition risks remain. Pfizer’s COVID revenue is declining, major products face future patent expirations, and one valuation analysis placed fair value near the current trading range, limiting perceived upside.

Pfizer Price Performance

Shares of NYSE:PFE opened at $29.46 on Thursday. The company has a market cap of $167.90 billion, a price-to-earnings ratio of 38.76, a PEG ratio of 2.04 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a 50 day simple moving average of $28.46 and a 200 day simple moving average of $26.74. Pfizer Inc. has a one year low of $23.62 and a one year high of $30.44.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the company earned $0.78 EPS. Pfizer's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Cantor Fitzgerald boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Saturday, October 10th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, October 13th. Five research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.72.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.